Renal cell cancer treatment patterns and clinical outcomes

• Research type

  Research Study

• Full title

  Descriptive Epidemiology, Treatment Patterns, and Outcomes of Patients with Renal Cell Carcinoma in England: A Retrospective Cohort Study Using SACT Data and Cancer Registry (DORCES)

• IRAS ID

  290156

• Contact name

  Alison Booth

• Contact email

  alison.booth@evidera.com

• Sponsor organisation

  Bristol-Myers Squibb Company

• Duration of Study in the UK

  1 years, 0 months, 1 days

• Research summary

  Kidney cancer is the seventh most common cancer in the UK. Eighty percent of kidney cancer cases are renal cell carcinoma, or RCC. RCC is the most common kidney cancer in adults.

  The most recent data on survival from kidney cancer in England are from 2013-2017. About two-thirds of people with kidney cancer were still alive five years after being diagnosed. At 10 years, only about half were still alive.

  Patients whose RCC has not spread from the original site often have surgery. Drug treatment is usually given for more advanced RCC. The drugs target the factors that help the cancer grow. For example, they may change proteins or blood vessels.

  Until 2018, the first treatment for most people with advanced RCC was one of the drugs called tyrosine kinase inhibitors. Current guidelines state these patients should start with nivolumab plus ipilimumab. As new treatment options become available, it is not clear how patients are being treated now and how survival has changed over time.

  This study will answer several research questions. What are the trends in RCC treatment in England? What are patients’ current survival rates? How do these trends vary depending on different patient factors?
  • Disease stage at diagnosis
  • Type of cancer cells
  • Whether treatment is first, second, or third given after diagnosis
  • Year of diagnosis
  • Use of surgery

  The study will use three databases. One database will be of all registered cancer cases in England, another one will be of cancer drugs given, and a third one will be of hospital care. The data will include details about the patients, such as their age and sex. It will also include information about their RCC, including their treatments and survival. The study will look at patients overall and according to when they were diagnosed. It will also study other aspects that might affect the patients’ care and response.

• REC name

  North East - Tyne & Wear South Research Ethics Committee

• REC reference

  21/NE/0044

• Date of REC Opinion

  10 Feb 2021

• REC opinion

  Favourable Opinion